Chinese CDC Researchers Compare Influenza and COVID-19 Etiology, Pathogenesis, Vaccine and Antiviral Development

A team of researchers at the Chinese Center for Disease Control and Prevention has published a side-by-side comparison of influenza and COVID-19, examining how the two respiratory pathogens differ in etiology and pathogenesis and in the development of vaccines and antiviral drugs.

The work was carried out at the NHC Key Laboratories of Biosafety and of Medical Virology and Viral Diseases and at the Chinese National Influenza Center, all based at the National Institute for Viral Disease Control and Prevention in Beijing.

Influenza virus and coronavirus are described in the review as two kinds of pathogens that exist widely in nature and are common emerging causes of respiratory tract infections in humans.

In December 2019, the novel coronavirus SARS-CoV-2 emerged, causing severe respiratory infection named COVID-19 and raising a global pandemic that had persisted for almost three years. Influenza virus, a seasonally circulating respiratory pathogen, has caused four global pandemics in humans since 1918 through the emergence of novel variants.

Vaccination and antiviral drugs are considered to have positive roles, as well as several limitations, in the prevention and control of both diseases. The authors argue that comparative understandings would be helpful to prevention and control efforts.

On the drug front, the review catalogs compounds acting on viral replication and on the host. Zanamivir can reduce disease duration to 1–2.5 days when treatment begins within 48 hours of symptom onset, and resistant strains with declined sensitivity have emerged.

Peramivir, given by intravenous injection, produced a median time to symptom alleviation of 29.1 hours, showed no difference from oseltamivir in time to defervescence with viral titers declining, and — like laninamivir, an inhalable, structurally modified form of zanamivir — requires only a single daily dose. Laninamivir’s 40 mg octanoate formulation showed no statistically significant difference from oseltamivir. Peramivir, however, has low oral bioavailability.

The M2 ion channel blockers amantadine and rimantadine show severe drug resistance in circulating influenza virus and are not recommended for clinical use. Newer agents include the cap-dependent endonuclease inhibitor baloxavir marboxil, which produced a shorter duration of detectable virus than oseltamivir (24 versus 72 hours, p < 0.001), even though median time to symptom improvement was nearly identical in the two groups (53.5 versus 53.8 hours); baloxavir also has high plasma retention time. The oral polymerase inhibitor pimodivir achieved 100% survival in a mouse model when administered 96 hours after infection, while favipiravir showed faster symptom alleviation than placebo — a median of 82.3 hours versus 97.3 hours — along with viral load reductions, though it carries possible adverse reactions. Compounds such as nucleozin and several hemagglutinin inhibitors — including the fusion inhibitor arbidol, whose inhibition concentrations reach 12 micromolar against H3N2 and 13.3 micromolar against influenza B — remain not yet available as drugs.

The Chinese Center for Disease Control and Prevention, established in 1983 as the China Center for Preventive Medicine and reorganized on January 23, 2002, is an institution directly under the National Health Commission based in Changping, Beijing. As of 2016 it had 2,120 staff, of whom 1,876 were technical professionals, and it publishes or co-sponsors 16 journals, including China CDC Weekly and the Chinese Journal of Epidemiology.

During the COVID-19 pandemic, the institution uploaded the genetic sequence of SARS-CoV-2 to GISAID for global dissemination on January 10, 2020, and in 2022 shared a phylogenetic analysis of more than 32 independent introductions of the virus identified in China in the first quarter of that year. It also administers laboratories across the country, including a biosafety level 2 facility at the Wuhan Center for Disease Control.

The authors state that the review covers study progress in etiology, pathogenesis, and vaccine and antiviral drug development for the two diseases, with the aim of aiding their prevention and control.

Photo of author

Health Desk

Health Desk at Archyde.

The Hunger Games: Sunrise on the Reaping’ Review: Critics Call It Gripping, ‘Being Heumann’ on Apple TV